ACTX 401
Alternative Names: ACTX-401Latest Information Update: 09 Nov 2022
At a glance
- Originator Alcyone Lifesciences
- Developer Alcyone Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Spinal muscular atrophy
- Preclinical Charcot-Marie-Tooth disease
Most Recent Events
- 29 Sep 2022 Preclinical trials in Charcot-Marie-Tooth disease in USA (Parenteral) (Alcyone Therapeutics pipeline, September 2022)
- 18 May 2022 US FDA approves IND application for ACTX 401 in Spinal muscular atrophy
- 18 May 2022 Pharmacodynamics and adverse event data from a preclinical trials in Spinal muscular atrophy released by Alcyone Therapeutics